Patent intelligence · US
US 11834688
Ligase fusion proteins and application thereof
Ligase fusion proteins and application thereof
Patent details — US 11834688
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 5, 2023
- Expiration
- Nov 30, 2043
- Claims
- 28
- CPC classes
- A61K, A61K47/60, A61K47/6801, A61K47/68033
Quick answer
US 11834688 (Ligase fusion proteins and application thereof) is held by GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.. Status: granted. Granted Dec 5, 2023. Expires Nov 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K47/60, A61K47/6801, A61K47/68033, A61K47/6817, A61K47/6855
More from GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12391720
Salts and polymorphs of cethromycin for the treatment of disease
granted -
US 12377151
Immobilized endoglycosidase fusion protein and use thereof
granted -
US 12370266
Polymer composite nanomaterial encapsulation system
granted -
US 12318457
Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof
granted -
US 12312377
Biconjugatable labels and methods of use
granted -
US 12195454
Compounds for imaging tau proteins that accumulate in the brain
granted -
US 12102694
Radiolabeled compound producing method and producing apparatus, radiolabeled compound and radioisotope producing apparatus
granted -
US 11999748
Exatecan derivatives, linker-payloads, and conjugates and thereof
granted
Frequently asked questions
What is US patent 11834688?
US 11834688 (Ligase fusion proteins and application thereof) is held by GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.. Status: granted. Granted Dec 5, 2023. Expires Nov 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11834688?
GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.
When does US 11834688 expire?
Our index shows an expiration date of Nov 30, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.